Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.52 |
| ▸ | USP2 | O75604 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118654 | 0.84 | KMT2A (0.51) | ALDH1A1SMN1; SMN2TSHRKMT2A | |
| SCHEMBL5130970 | 0.82 | GRM5 (0.45) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL5115717 | 0.80 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2CYP3A4TSHRMEN1 | |
| SCHEMBL5130909 | 0.79 | GRM5 (0.46) | ALDH1A1SMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL5125959 | 0.78 | GRM5 (0.60) | CYP3A4MEN1KMT2ACYP1A2 | |
| SCHEMBL5116452 | 0.78 | GRM5 (0.44) | ALDH1A1SMN1; SMN2USP2HPGDTSHR | |
| SCHEMBL5129768 | 0.78 | GRM5 (0.54) | ALDH1A1 | |
| SCHEMBL5125577 | 0.78 | PKM (0.47) | ALDH1A1SMN1; SMN2HSD17B10USP2HPGD | |
| SCHEMBL5128124 | 0.78 | GRM5 (0.53) | ALDH1A1CYP3A4 | |
| SCHEMBL5120360 | 0.77 | HPGD (0.48) | ALDH1A1SMN1; SMN2HPGDMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| EP-1856107-A1 | PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS | Novartis AG (CH) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006089700-A1 | PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS | NOVARTIS AG (CH) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | GRM5, GRIK5, GRM1 | ALDH1A1 908/4885SMN1; SMN2 2698/4885HSD17B10 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.